Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector. The move is part of Ampersand’s strategy to establish a trans-Atlantic pharmaceutical development partnership through the Purna and MedPharm alliance.
This partnership has the potential to become a preferred trans-Atlantic provider for the development, manufacturing, and formulation of topical and transdermal pharmaceutical drugs. MedPharm currently operates as Ampersand’s topical and transdermal pharmaceutical development and manufacturing platform.
Deal Advisors: Achelous Partners acted as investment banking and financial adviser to Purna during the transaction.
Hidde van Kerckoven, Principal at Ampersand Capital Partners, commented: “Purna has built a reputation for quality, reliability, and customer partnership. We are excited to support the Purna team by providing strategic guidance, capital, and access to our life sciences network while preserving the company’s culture and customer-first approach.”
Established in 1986, Purna delivers contract services for developing and manufacturing powder, liquid, and semi-solid pharmaceutical products, according to GXP standards and specific client requirements. The company serves small start-ups through to multinational pharma companies.
Ampersand Capital Partners currently manages $3bn in assets with an exclusive focus on growth investments within healthcare sectors.
This acquisition continues a trend of active investment for the firm. In November 2024, GHO Capital Partners and Ampersand Capital signed a definitive agreement to acquire biologics contract development and manufacturing organisation (CDMO) Avid Bioservices in a $1.1bn cash transaction.
